Kara Davis, MD
Stanford University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kara Davis, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:30 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05865301 · Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available ImmunotherapyStanford University · recruiting · Lymphoid Leukemia · principal investigator
- Ph1NCT04088864 · CD22-CAR T Cells in Children and Young Adults With B Cell MalignanciesKara Lynn Davis · completed · B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in childhood acute lymphoblastic leukemia.